a Ocean College , Zhejiang University , Zhoushan , China.
b College of Pharmaceutical Science , Zhejiang University , Hangzhou , China.
Drug Deliv. 2018 Nov;25(1):341-352. doi: 10.1080/10717544.2018.1425778.
Metastasis is one of the major obstacles for successful therapy of breast tumor. To inhibit the metastasis and growth of breast tumor simultaneously, a Celastrol (Cela) loaded glucolipid-like conjugates (CSOSA/Cela) with αvβ3-ligand Tetraiodothyroacetic acid (TET) modification (TET-CSOSA/Cela) were established to block nuclear factor-kappa B (NF-κB) signaling pathway. The distribution of TET-CSOSA was remarkably increased in lung metastasis and primary tumor of 4T1 tumor-bearing mice by means of αvβ3 receptor-mediated interaction. The results demonstrated that TET-CSOSA/Cela significantly suppressed Bcl-2 activation of lung metastatic cells and reduced MMP-9 expression of 4T1 breast tumor cells by blocking NF-κB. The inhibitory rates of TET-CSOSA/Cela against lung metastasis and primary tumor were raised to 90.72 and 81.15%, compared to those of Celastrol (72.15 and 46.40%), respectively. All results demonstrated the αvβ3 receptor targeted TET-CSOSA/Cela micelles exhibited great potential in treating lung metastasis and primary tumor simultaneously via blocking NF-κB signaling pathway.
转移是乳腺癌成功治疗的主要障碍之一。为了同时抑制乳腺癌的转移和生长,建立了载有姜黄素(Cela)的葡脂样缀合物(CSOSA/Cela),并用 αvβ3 配体四碘甲状腺原氨酸(TET)进行了修饰(TET-CSOSA/Cela),以阻断核因子-κB(NF-κB)信号通路。通过 αvβ3 受体介导的相互作用,TET-CSOSA 在荷 4T1 肿瘤小鼠的肺转移和原发性肿瘤中的分布明显增加。结果表明,TET-CSOSA/Cela 通过阻断 NF-κB 显著抑制了肺转移细胞中 Bcl-2 的激活,并降低了 4T1 乳腺癌细胞中 MMP-9 的表达。与 Celastrol(分别为 72.15%和 46.40%)相比,TET-CSOSA/Cela 对肺转移和原发性肿瘤的抑制率分别提高到 90.72%和 81.15%。所有结果表明,通过阻断 NF-κB 信号通路,αvβ3 受体靶向的 TET-CSOSA/Cela 胶束在同时治疗肺转移和原发性肿瘤方面具有很大的潜力。